p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

被引：0
|
作者：
Hélène Vanacker
Isabelle Treilleux
Camille Schiffler
Ivan Bieche
Mario Campone
Anne Patsouris
Monica Arnedos
Paul H. Cottu
Jean-Philippe Jacquin
Florence Dalenc
Antoine Pinton
Nicolas Servant
Valéry Attignon
Etienne Rouleau
Alain Morel
François Legrand
Marta Jimenez
Fabrice Andre
Thomas Bachelot
机构：
[1] Centre Léon Bérard,
[2] Institut Curie,undefined
[3] Institut de cancérologie de l’ouest Pays de Loire Nantes-Angers,undefined
[4] Gustave Roussy,undefined
[5] Institut de Cancérologie Lucien Neuwirth,undefined
[6] ICR,undefined
[7] Institut Universitaire du Cancer de Toulouse,undefined
[8] Oncopole,undefined
[9] Univ Angers,undefined
[10] Nantes Université,undefined
[11] Inserm,undefined
[12] CNRS,undefined
[13] CRCI2NA,undefined
[14] SFR ICAT,undefined
[15] UNICANCER R&D,undefined
来源：
British Journal of Cancer | 2024年 / 130卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：613 / 619
页数：6
相关论文
共 50 条
  • [1] p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane
    Vanacker, Helene
    Treilleux, Isabelle
    Schiffler, Camille
    Bieche, Ivan
    Campone, Mario
    Patsouris, Anne
    Arnedos, Monica
    Cottu, Paul H.
    Jacquin, Jean-Philippe
    Dalenc, Florence
    Pinton, Antoine
    Servant, Nicolas
    Attignon, Valery
    Rouleau, Etienne
    Morel, Alain
    Legrand, Francois
    Jimenez, Marta
    Andre, Fabrice
    Bachelot, Thomas
    BRITISH JOURNAL OF CANCER, 2024, 130 (04) : 613 - 619
  • [2] PAK4 regulates sternness and progression in endocrine resistant ER-positive metastatic breast cancer
    Santiago-Gomez, Angelica
    Kedward, Thomas
    Simoes, Bruno M.
    Dragoni, Ilaria
    NicAmhlaoibh, Roisin
    Trivier, Elisabeth
    Sabin, Verity
    Gee, Julia M.
    Sims, Andrew H.
    Howell, Sacha J.
    Clarke, Robert B.
    CANCER LETTERS, 2019, 458 : 66 - 75
  • [3] Inverse relationship between ER-β and SRC-1 predicts outcome in endocrine-resistant breast cancer
    E Myers
    F J Fleming
    T B Crotty
    G Kelly
    E W McDermott
    N J O'Higgins
    A D K Hill
    L S Young
    British Journal of Cancer, 2004, 91 : 1687 - 1693
  • [4] Inverse relationship between ER-β and SRC-1 predicts outcome in endocrine-resistant breast cancer
    Myers, E
    Fleming, FJ
    Crotty, TB
    Kelly, G
    McDermott, EW
    O'Higgins, NJ
    Hill, ADK
    Young, LS
    BRITISH JOURNAL OF CANCER, 2004, 91 (09) : 1687 - 1693
  • [5] Outcomes of Everolimus plus Exemestane in ER-positive, HER2-negative Heavily Pre-treated Metastatic Breast Cancer Patients: A Real Life Multicentre Experience
    Desai, P.
    Hogg, M.
    CLINICAL ONCOLOGY, 2018, 30 (06) : E42 - E43
  • [6] Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane
    Lee, Kyoungmin
    Noh, Eunjin
    Moon, Seok Joo
    Joo, Yoonjung Yoonie
    Kang, Eun Joo
    Seo, Jae Hong
    Park, In Hae
    CANCER MEDICINE, 2023, 12 (05): : 5461 - 5470
  • [7] Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy
    Larsen, Mathilde S.
    Bjerre, Karsten
    Lykkesfeldt, Anne E.
    Giobbie-Hurder, Anita
    Laenkholm, Anne-Vibeke
    Henriksen, Katrine L.
    Ejlertsen, Bent
    Rasmussen, Birgitte B.
    BREAST, 2012, 21 (05): : 662 - 668
  • [8] Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer
    Kok, Marleen
    Koornstra, Rutger H.
    Margarido, Tania C.
    Fles, Renske
    Armstrong, Nicola J.
    Linn, Sabine C.
    Van't Veeri, Laura J.
    Weigelt, Britta
    JOURNAL OF PATHOLOGY, 2009, 218 (03): : 316 - 326
  • [9] Hyperactive FOXA1 activates super-enhancer-engaged HIF2α/EPAS1 to promote endocrine-resistant metastatic ER-positive breast cancer
    Fu, Xiaoyong
    Pereira, Resel
    De Angelis, Carmine
    Veeraraghavan, Jamunarani
    Shea, Martin J.
    Nanda, Sarmistha
    Feng, Qin
    Jeselsohn, Rinath
    O'Malley, Bert W.
    Brown, Myles
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2018, 78 (04)
  • [10] AP-1 as a potential mediator of resistance to the cyclin-dependent kinase (CDK) 4/6-inhibitor palbociclib in ER-positive endocrine-resistant breast cancer
    De Angelis, Carmine
    Nardone, Agostina
    Cataldo, Maria Letizia
    Veeraraghavan, Jamunarani
    Fu, Xiaoyong
    Giuliano, Mario
    Malorni, Luca
    Jeselsohn, Rinath
    Osborne, Kent C.
    Schiff, Rachel
    CANCER RESEARCH, 2018, 78 (04)
12345